Ionis Pharmaceuticals Inc logo

Ionis Pharmaceuticals Inc(IONS)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL
2-STAR RATING
PASS
LAST CLOSE
$29.06
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for IONS

11/13/2026: IONS (2-star) is currently NOT-A-BUY. Pass it for now.

Ionis Pharmaceuticals is a commercial-stage biotechnology company specializing in RNA-targeted therapeutics for serious and rare diseases. The company's main strengths lie in its foundational antisense technology platform, validated royalty streams from partnered drugs like Spinraza, and a robust balance sheet. Its primary growth opportunity stems from the commercial expansion of newly launched treatments such as Wainua and Tryngolza. However, key risks include persistent operating cash burn, execution hurdles with recent product rollouts, and intense competition from alternative genetic medicine modalities. The stock suits growth-oriented biotech investors willing to tolerate clinical volatility while monitoring long-term pipeline execution and cash-flow milestones.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitAppeals to growth investors seeking exposure to innovative RNA platform pipelines, though near-term revenue growth remains lumpy.
Momentum investorStrong fit while signal remains positiveMomentum appeal depends closely on positive clinical trial readouts and regulatory catalysts driving short-term price movement.
Value investorWeak fitLacks consistent profitability and traditional earnings metrics, making traditional value valuation challenging.
Dividend investorWeak fitThe company does not pay dividends, reinvesting all capital into drug development.
Low-risk investorWeak fitHigh clinical trial risks and stock price volatility make it unsuitable for conservative, low-risk mandates.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical trial results and regulatory decisions frequently trigger sharp share price swings.
Valuation riskMedium / highValuation relies heavily on long-term pipeline potential rather than current earnings multiples.
Competition risk (RNA and genetic medicine rivals)HighAggressive competition from alternative modalities like siRNA and gene editing threatens market share.
Business qualityMediumStrong proprietary platform and high-profile pharma partnerships validate structural quality, offset by lack of net profitability.
Dividend incomeLow / noneNo dividend is paid to investors.
Execution riskHighSuccessful commercial rollouts and clinical trial execution are vital to achieving positive cash flow.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 4.84B USD
Price to earnings Ratio -
1Y Target Price 68.48
Price to earnings Ratio -
1Y Target Price 68.48
Volume (30-day avg) 4.0M shares
Beta 0.4
52 Weeks Range 27.25 - 86.74
Updated Date 11/15/2026
52 Weeks Range 27.25 - 86.74
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -3.35

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Steep Decline
PRICE PATH

Steep Decline

The stock price has dropped sharply with strong downward pressure.

Highly Choppy
PRICE STABILITY

Highly Choppy

The stock has experienced frequent, large price swings that make its near-term movement less predictable.

Analysis of Past Performance

Type Stock
Historic Profit 85.43%
Avg. Invested days 65
Today’s Advisory PASS
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 4.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
IONS receives a 3-star rating, supported by solid company fundamentals, and strong analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
IONS has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, solid earnings growth (+16.1%) and solid revenue growth (+33.9%) are partially offset by weak cash generation (FCF margin -33.9%), weak profitability (net margin -40.4%), modest insider ownership of 1.48%.

Financial Health Rating

★★★★★
IONS's financial health is supported by moderate liquidity, including working-capital and asset support (WC/assets 62.7%). Cash strength is soft (2 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Free-cash-flow growth is IONS's strongest growth driver at +41.4% FY2025 versus FY2024 (strong, 5 stars). Revenue growth (+33.9%, solid) and earnings growth (+16.1%, solid) are also constructive, though not equally high across every growth measure.

Ownership

★★★★★
Institutional ownership is 111.7% and approximately 99.2% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 1.48% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

FMR Inc 14.80%
Capital World Investors 13.02%
BlackRock Inc 6.43%
Vanguard Portfolio Management, LLC 4.72%
Wellington Management Company LLP 4.60%

Unit Economics (Per $1K Revenue)

★★★★★
IONS generates approximately $983 of gross profit, $-405 of operating income, and $-339 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Operating losses and cash burn explain the 1-star rating, with weak cash conversion and weak capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: -0.26% (Tax Credit)

Quantitative Style Profile

★★★★★
IONS has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while soft valuation.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Commercial Product SalesDirect sales of proprietary rare disease and specialty medicines.Direct product sales represent high-quality revenue, though they currently form a smaller portion of total sales.
Royalties and LicensingRoyalty percentages on partner-commercialized drugs like Spinraza and milestone payments.Royalties provide a steady, lower-overhead income stream backed by major pharmaceutical distributors.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Valuation

Trailing PE -
Forward PE 90.91
Enterprise Value 4.59B
Price to Sales(TTM) 5.04
Enterprise Value 4.59B
Price to Sales(TTM) 5.04
Enterprise Value to Revenue 4.78
Enterprise Value to EBITDA 135.77
Shares Outstanding 166.55M
Shares Floating 165.18M
Shares Outstanding 166.55M
Shares Floating 165.18M
Percent Insiders 1.48
Percent Institutions 111.68

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.